Alligator Bioscience: Invitation to Alligator Bioscience’s earnings call on 26 August 2026

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company whose principal asset is a financial interest in the HER2-targeting antibody programme HLX22, will publish its interim report for April – June 2026 on Wednesday, 26 August 2026, at 8:00 a.m. CEST. On the same day, Alligator will host a webinar and conference call for investors, analysts and media at 3:00 p.m. CEST / 9:00 a.m. EDT, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report. The presentation will be followed by a Q&A session. The call will be held in English. Attendees are required to register in advance via this link (https://events.teams.microsoft.com/event/3d3bc33b-a79c-43c9-a2b1-40a3624581c2@0e5aa457-8704-444a-a7c7-2f0fb62399a5) and are welcome to submit questions in advance to ir@alligatorbioscience.com. The full report will be available upon publication on Alligator’s website (https://alligatorbioscience.se/en/investors/financial-reports/). ------------------------------------------------------------------------------ For further information, please contact: Søren Bregenholt, CEO E-mail: soren.bregenholt@alligatorbioscience.com (mailto:sbr@alligatorbioscience.com?subject=Alligator%20Bioscience%20to%20Present%20Additional%20data%20of%20ATOR-1017%20First-in-Human%20Study%20via%20poster%20presentation%20at%20ASCO%20Annual%20Meeting%202022) Phone: +46 (0) 46 540 82 00 Johan Giléus, CFO E-mail: johan.gileus@alligatorbioscience.com Phone: +46 (0) 46 540 82 00 ------------------------------------------------------------------------------ The information was submitted for publication, through the agency of the contact persons set out above, at 8:45 a.m. CEST on 20 August 2026. ------------------------------------------------------------------------------ About Alligator Bioscience Alligator is a biotechnology company that has historically focused on tumor-directed immuno-oncology. Following a strategic refocus, Alligator is prioritizing the value of its economic interest in HLX22, an anti-HER2 monoclonal antibody being developed by Shanghai Henlius Biotech Inc., from which Alligator is entitled to a share of revenues without incurring development costs. Alligator has discontinued further internal development of mitazalimab and is seeking to out-license or divest the asset in the near term. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com (https://www.alligatorbioscience.se/en). Attachments ------------------------------------------------------------------------------ Invitation to Alligator Bioscience’s earnings call on 26 August 2026 (https://storage.mfn.se/a724f8d0-c54e-4e90-9f06-4e2c137cdc79/invitation-to-alligator-biosciences-earnings-call-on-26-august-2026.pdf)